CA1850532047
© Globe Newswire
12.12.2025
CMND
LISTED
NASDAQ
Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment
News Preview
Vancouver, Canada, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of a review a...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.12.2025
CMND
LISTED
NASDAQ
Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
News Preview
Vancouver, Canada, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that on December 10, 2025, th...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
CMND
LISTED
NASDAQ
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification
News Preview
Vancouver, Canada, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, announced today that on December 4, 2025, the Com...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
01.12.2025
CMND
LISTED
NASDAQ
Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial
News Preview
Vancouver, Canada, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, recently announced three transformative milestone...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
25.11.2025
CMND
LISTED
NASDAQ
Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial
News Preview
First patient recruited at leading Israeli site accelerating enrollment momentum across global study of CMND-100...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.11.2025
CMND
LISTED
NASDAQ
Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site
News Preview
Prestigious Hadassah Medical Center Joins Yale, Johns Hopkins, Tel Aviv Sourasky and IMCA, in Evaluating the Company’s proprietary non-hallucinogenic MEAI-based oral drug candidate...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
CMND
LISTED
NASDAQ
Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment
News Preview
The notice was received by the China National Intellectual Property Administration...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
CMND
LISTED
NASDAQ
Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
News Preview
Milestone advances MEAI-based therapy targeting a global Alcohol Use Disorder treatment market projected to surpass $20 billion by 2032...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.10.2025
CMND
LISTED
NASDAQ
Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy
News Preview
Vancouver, Canada, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of a U.S. patent...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.10.2025
CMND
LISTED
NASDAQ
Clearmind Medicine CEO Dr. Adi Zuloff-Shani to Speak at Women in Psychedelic Leadership Webinar
News Preview
Vancouver, Canada, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, is proud to announce that its CEO, Dr. Adi Zuloff...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.10.2025
CMND
LISTED
NASDAQ
Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement
News Preview
Vancouver, Canada, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogens-derived therapeutics to solve major under-treated health problems, today announced the appointment of Mary-Elizabet...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.10.2025
CMND
LISTED
NASDAQ
Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
News Preview
Vancouver, Canada, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the enrollment of the last patient f...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
20.10.2025
CMND
LISTED
NASDAQ
Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders
News Preview
Vancouver, Canada, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of a U.S. patent app...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.09.2025
CMND
LISTED
NASDAQ
Clearmind Medicine’s Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies
News Preview
Vancouver, Canada, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the successful convening of its inau...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
CMND
LISTED
NASDAQ
Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities
News Preview
Vancouver, Canada, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has entered into securities...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.07.2025
CMND
LISTED
NASDAQ
Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
News Preview
Vancouver, Canada, July 30, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the filing of a new international pat...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.07.2025
CMND
LISTED
NASDAQ
Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled
News Preview
Vancouver, Canada, July 15, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the expansion of its Phase I/IIa cli...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.07.2025
CMND
LISTED
NASDAQ
Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center
News Preview
Vancouver, Canada, July 03, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received Institutional R...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.06.2025
CMND
LISTED
NASDAQ
Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder
News Preview
Vancouver, Canada, June 30, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced a historic milestone: the first part...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.06.2025
CMND
LISTED
NASDAQ
Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market
News Preview
Vancouver, Canada, June 27, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the addition of Hadassah-University...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.06.2025
CMND
LISTED
NASDAQ
Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics
News Preview
Vancouver, Canada, June 24, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced earlier this month it has engaged a promin...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.06.2025
CMND
LISTED
NASDAQ
Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics
News Preview
Vancouver, Canada, June 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.04.2025
CMND
LISTED
NASDAQ
Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites
News Preview
The Company is now preparing for the enrollment of the first patient to receive Clearmind’s innovative treatment as part of the trial...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.04.2025
CMND
LISTED
NASDAQ
Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts
News Preview
Vancouver, Canada, April 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce its upcoming live webinar ti...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.04.2025
CMND
LISTED
NASDAQ
Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder
News Preview
Vancouver, Canada, April 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today that it has initiated its Phase I/II...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.04.2025
CMND
LISTED
NASDAQ
Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment
News Preview
The clinical trial is designed to evaluate the safety, tolerability and efficacy of Clearmind’s innovative, psychedelic-derived, MEAI-based compound in individuals with alcohol addiction...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.03.2025
CMND
LISTED
NASDAQ
Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones
News Preview
Vancouver, Canada, March 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today that its innovative drug candidate,...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.03.2025
CMND
LISTED
NASDAQ
Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea
News Preview
Vancouver, Canada, March 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of a patent by the...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2025
CMND
LISTED
NASDAQ
Clearmind Medicine Announces Shareholders Meeting Results
News Preview
Vancouver, Canada, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce that all of the matters put f...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2025
CMND
LISTED
NASDAQ
Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
News Preview
Vancouver, Canada, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of a European patent...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.12.2024
CMND
LISTED
NASDAQ
Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute
News Preview
Company recently signed a non-binding term sheet with Dr Glitter Pty Ltd for mutual development in ActivCrystal™ Format...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.12.2024
CMND
LISTED
NASDAQ
Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial
News Preview
Vancouver, Canada, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced it has received Institutional Review...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.10.2024
CMND
LISTED
NASDAQ
Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site
News Preview
FDA approval for the IND submission to conduct its trial already secured...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2024
CMND
LISTED
NASDAQ
Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy
News Preview
Innovative drug treatment developed in collaboration with SciSparc aims to enhance safety and efficacy in mental health and addiction care...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.09.2024
CMND
LISTED
NASDAQ
Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment
News Preview
Innovative compounds designed to address critical unmet needs in PTSD treatment...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.09.2024
CMND
LISTED
NASDAQ
Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
News Preview
Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacyin Mental Health and Addiction Treatments...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.08.2024
CMND
LISTED
NASDAQ
Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment
News Preview
Vancouver, Canada, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced the publication of its patent application u...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.08.2024
CMND
LISTED
NASDAQ
Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment
News Preview
Vancouver, Canada, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received a new patent ap...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.08.2024
CMND
LISTED
NASDAQ
Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders
News Preview
Vancouver, Canada, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the submission of a patent application under the int...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.07.2024
CMND
LISTED
NASDAQ
Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism
News Preview
Vancouver, Canada, July 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that the U.S. Food and Drug Adminis...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.07.2024
CMND
LISTED
NASDAQ
Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss
News Preview
Vancouver, Canada, July 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced that it has submitted an additional patent...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.07.2024
CMND
LISTED
NASDAQ
Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference
News Preview
Vancouver, Canada, July 12, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces its participation in the upcoming Psychedel...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.06.2024
CMND
LISTED
NASDAQ
Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment
News Preview
Vancouver, Canada, June 28, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces advancement in its proprietary MEAI- based...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.05.2024
CMND
LISTED
NASDAQ
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
News Preview
The global market of no- and low-alcohol beverages estimated at over $13 billion in 2023...
Themefolio
Profiler
Peergroup
© Newsfile
28.09.2023
CMND
LISTED
NASDAQ
Clearmind Medicine to Present at the LD Micro Main Event XVI Investor Conference on October 4th
News Preview
Tel Aviv, Israel and Vancouver, British Columbia--(Newsfile Corp. - September 28, 2023) - Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND) (FSE: CWY) ("Clearmind" or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that Dr...
Themefolio
Profiler
Peergroup
© Newsfile
28.09.2022
CMND
LISTED
NASDAQ
CSE Bulletin: Consolidation - Clearmind Medicine Inc. (CMND)
News Preview
Toronto, Ontario--(Newsfile Corp. - Le 28 septembre/September 2022) - Clearmind Medicine Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every thirty (30) pre-consolidated common shares. As a result, the outstanding shares of the company wi...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
